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Abstract
Background: The implantable loop recorder (ILR) is a useful tool for diagnosis of syncope or 
palpitations. Its easy use and safety have extended its use to secondary hospitals (those without 
an Electrophysiology Lab). The aim of the study was to compare results between secondary and 
tertiary hospitals.
Methods: National prospective and multicenter registry of patients with an ILR inserted for 
clinical reasons. Data were collected in an online database. The follow-up ended when the first 
diagnostic clinical event occurred, or 1 year after implantation. Data were analyzed according 
to the center of reference; hospitals with Electrophysiology Lab were considered Tertiary Hospi-
tals, while those hospitals without a lab were considered Secondary Hospitals.
Results: Seven hundred and forty-three patients (413 [55.6%] men; 65 ± 16 year-old): 
655 (88.2%) from Tertiary Centers (TC) and 88 (11.8%) from Secondary Centers (SC). 
No differences in clinical characteristics between both groups were found. The electrophysi-
ologic study and the tilt table test were conducted more frequently in Tertiary Centers. Fol-
low-up was conducted for 680 (91.5%) patients: 91% in TC and 94% in SC. There was  
a higher rate of final diagnosis among SC patients (55.4% vs. 30.8%; p < 0.001). Tertiary 
Hospital patients showed a trend towards a higher rate of neurally mediated events (20% 
vs. 4%), while bradyarrhythmias were more frequent in SC (74% vs. 60%; p = 0.055).  
The rate of deaths and adverse events was similar in both populations.
Conclusions: Patients with an ILR in SC and TC have differences in terms of the use of 
complementary tests, but not in clinical characteristics. There was a higher rate of diagnosis 
in Secondary Hospital patients. (Cardiol J 2015; 22, 3: 241–246)
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Introduction
The implantable loop recorder (ILR) is 
a valuable tool for the diagnosis of clinical situations 
associated with paroxysmal arrhythmias. Since 
the first cases in 1998 [1], several studies have 
documented the role of the ILR in the research of 
syncopal episodes [2], palpitations [3], atrial fibril-
lation [4], risk stratification in infarction [5], or the 
study of cryptogenic stroke [6].
The majority of these studies have been 
conducted in tertiary centers of reference, with 
a highly selected population and high degree of 
specialization, which might introduce a certain bias, 
both regarding population and in results obtained. 
The ease of device implantation has extended its 
use among general cardiologists, and has allowed 
its use as a first line tool in centers without an 
Electrophysiology Lab. Neither the indications 
nor the results of the device in this setting have 
been described. The objective of the present study 
is to compare the results of the ILR (Reveal Plus/ 
/DX/XT®, Medtronic, Inc.) in a non-selected patient 
population from centers with and without Electro-
physiology Lab.
Methods
This is a sub-study of the Reveal Spanish 
Registry [7], which was designed as a prospective, 
observational and multicenter study on a national 
level. All centers where ILR devices are inserted 
were invited to take part. All patients who had 
a Reveal Plus® or Reveal XT-DX® implanted between 
April 2006 and December 2008 were included. 
No exclusion criteria were implemented, and the 
device parameters were programmed according 
to the choice of each professional conducting the 
procedure.
Those centers with an Electrophysiology Lab 
were defined as Tertiary Centers (TC group), while 
centers without an Electrophysiology Lab were 
defined as Secondary Centers (SC group).
Structural heart disease and bundle branch 
block were defined according to the definitions of 
previously published studies [8, 9].
Baseline data, as well as data about electro-
gram interpretation, final diagnosis and treatment, 
were included in the database as provided by the 
corresponding local investigator. Event was de-
fined as the presentation of syncope, pre-syncope 
or palpitations which reproduced the patient’s 
symptoms, or the presence of a significant ar-
rhythmia detected by the device, as defined in 
clinical guidelines [10]. Any event considered 
significant by the responsible physician and 
which led to a final diagnosis was considered 
a diagnostic event.
Follow-up visits were scheduled according to 
the investigators’ preference. Follow-up was ended 
when a diagnostic event occurred, or at the end of 
the follow-up period. For those patients without 
any events, follow-up at least of 12 months was 
requested.
Data were collected in electronic format or 
in paper forms, if it was required by the center. 
Electrograms could be sent in an electronic format 
to the Research Committee for its interpretation, 
if the physician considered it necessary. All data 
were stored in a database created for that purpose 
(MS Access Microsoft Corporation 2003). All those 
abnormal or inconsistent data were subject to a new 
analysis by the Research Committee.
Statistical analysis
Continuous variables are presented as mean 
and standard deviation or median (range), if dis-
tribution is not normal. Qualitative variables were 
analyzed using frequency and percentage tables. 
Comparison between arms was conducted with 
Student’s t-test or Mann-Whitney test for continu-
ous variables, and with c2 or Fisher’s exact test 
for proportions. The hypothesis was considered 
significant if the value of p was below 0.05. The 
SPSS program (v16.0.1, Chicago, Ill, USA) was 
used for analysis.
Results
Study centers and population
Forty centers took part in the registry; out 
of these, 30 (75%) were TCs and 10 (25%) were 
SCs. Seven hundred and forty-three ILRs were im-
planted: 655 (88.2%) in TCs, and 88 (11.8%) in SCs.
The baseline characteristics of the study 
population, and the results of tests conducted, 
classified according to the type of center, ap-
pear on Table 1. No significant differences were 
observed in terms of gender, age, prevalence of 
hypertension or diabetes, between both groups, 
nor in prevalence of structural heart disease (35% 
vs. 30%), left ventricular ejection fraction, or 
bundle branch block.
Cases were classified into four categories, ac-
cording to the reason for implantation: single syn-
cope, recurrent syncope, pre-syncope, and others 
(which included the rest of causes for implantation). 
Both populations presented a similar distribution 
in terms of cause for implantation (Table 1).
242 www.cardiologyjournal.org
Cardiology Journal 2015, Vol. 22, No. 3
Diagnostic tests
Carotid sinus massage (CSM) was conducted 
more frequently in the TC group (50 vs. 36%, p = 
= 0.020), though no differences were found in the age 
of both populations. There was a trend to perform 
tilt table test more frequently in TCs (33% vs. 22%; 
p = 0.07), and, as expected, the electrophysiologic 
study (EPS) was conducted more frequently in 
Table 1. Baseline characteristics, test performed, events, diagnosis, and treatment of patients according 
to the type of hospital.
Tertiary Centers Secondary Centers P
Patients 655 88
Age [years] 64.7 ± 16.5 67.1 ± 14.5 0.271 
Gender (men) 364 (55.6%) 49 (55.7%) 0.966 
Left ventricular ejection fraction: 0.365
> 55% 460 (70.2%) 67 (76.1%)
35–55% 75 (11.5%) 10 (11.4%)
< 35% 8 (1.2%) 0 (0%)
No data 112 (17.1%) 11 (12.5%)
Structural heart disease 197 (30.1%) 31 (35.2%) 0.325 
Hypertension 307 (46.9%) 45 (51.1%) 0.347 
Diabetes 105 (16.0%) 14 (15.9%) 0.830 
Bundle branch block (BBB) 158 (24.1%) 25 (28.4%) 0.381
Right BBB 40 (6.1%) 6 (6.8%)
Left BBB 55 (8.4%) 9 (10.2%)
Others 63 (9.6%) 10 (11.4%)
Electrophysiologic study: 0.001
Normal 245 (37.4%) 13 (14.8%)
Pathologic 45 (6.9%) 8 (9.1%)
Non performed 365 (55.7%) 67 (76.1%)
Carotid sinus massage:
Performed 330 (50.4%) 32 (36.3%) 0.013
Head up tilt test: 0.07
Positive 72 (11.0%) 10 (11.3%)
Negative 139 (21.2%) 10 (11.3%)
Non performed 444 (67.8%) 68 (77.3%)
Cause of implant: 0.355
Recurrent syncope 501 (76.5%) 67 (76.1%)
Single syncope 98 (15.0%) 9 (10.2%)
Presyncope 34 (5.2%) 9 (10.2%)
Others 22 (3.3%) 3 (3.4%)
Lost patients 58 (8.8%) 5 (5.7%) 0.417 
Events* 275 (46.6%) 50 (60.2%) 0.015
Final diagnosis* 184 (30.8%) 46 (55.4%) < 0.001
Final treatment* 166 (27.8%) 45 (54.2%) < 0.001
Diagnosis of the event**: 0.084
Bradyarrhythmia 110 (59.8%) 34 (73.9%)
Tachyarrhythmia 25 (13.6%) 7 (15.2%)
Neuromediated 37 (20.1%) 2 (4.3%)
Other 12 (6.5%) 3 (6.5%)
*Percentages refer to patients with follow-up; **Percentages refer to patients with final diagnosis
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patients with the ILR implanted in TCs. The most 
common finding among patients with abnormal EPS 
results was first or second degree atrioventricular 
block (n = 16), followed by induced supraventricu-
lar tachycardias (n = 15).
Follow-up
All results refer to the patients with follow-up 
data (680 patients; 591 from TCs (91%) and 
89 (94%) from SCs). The baseline characteristics of 
63 patients without follow-up showed no differen-
ces from those of the rest of the population. The 
average duration of follow-up was 321.5 ± 174.4 days 
for patients from TCs and 274.6 ± 190.5 days for 
SC patients (p = 0.02).
There were 414 events (350 in TCs and 64 in 
SCs) in 325 patients (275 TC patients and 50 SC 
patients) (47% vs. 60% p = 0.015). The number 
of events per patient was similar in both popula-
tions (1.3 vs. 1.2). The type of event recorded 
(syncope, pre-syncope, palpitations and automatic 
activations) had a similar distribution between 
both groups.
A final diagnosis was obtained in 184 pa-
tients (30.8%) from TCs and 46 (55.4%) from SCs 
(p < 0.001). The average time to diagnosis was 
similar in both groups (212 ± 193 days in SCs vs. 
225 ± 175 days in TCs; p = 0.662).
The type of final diagnosis was different in both 
groups. In the TC group, the rate of neurally medi-
ated events was higher (20% vs. 4%; p = 0.006), 
while bradyarrhythmias were more frequent in the 
SC group (74% vs. 60%; p = 0.035). The proportion 
of events due to tachycardia or other causes was 
similar in both groups.
A similar proportion of patients with final di-
agnosis received specific treatment in both popula-
tions (90% in TCs and 98% in SCs).
Mortality
Eighteen (2.4%) deaths were recorded during 
follow-up (55.5% male patients; age 72.7 ± 8.5); 
10 (55.5%) of these patients had structural heart 
disease, and 7 (38.9%) presented abnormalities in 
their electrocardiograms. The cause of death could 
only be confirmed in 4 cases; 17 cases came from 
TCs (2.5% vs. 1.1%, p = 0.7).
Discussion
As far as we know, this is the first study which 
has compared ILR results between SC and TC. 
Results show that the performance of the device 
seems to be higher in those centers without Elec-
trophysiology Lab, probably due to the different 
diagnostic strategies used in both populations.
Regarding baseline characteristics of the popu-
lation, both groups present similar data in terms 
of age, distribution by gender, and comorbidities 
(diabetes, hypertension, bundle branch block), 
and the primary cause for implantation in both 
groups was recurrent syncope. The prevalence of 
structural heart disease in our population (30%) 
was similar to that in previous studies (28–33%), 
and so were the rest of baseline characteristics 
[11, 12]. We did not find significant differences 
between patients from TCs and SCs.
Diagnostic tests
The tests conducted in both populations show 
important differences, not only regarding EPS data, 
but also in other tests; this shows that a different 
diagnostic strategy was used in each group.
As expected, there were no significant differ-
ences in the use of echocardiography. EPS (44% 
vs. 26%, p < 0.05) were conducted more frequently 
in TCs, probably due to their higher availability. 
Something similar happened with the tilt table 
test, with a significant trend to be performed more 
frequently at TCs (33% vs. 22%; p = 0.07).
Even though the CSM is a simple clinical ma-
neuver, it was more frequently conducted in TCs 
(50% vs. 36%; p < 0.05), even when there were no 
differences between ages of both populations. The 
explanation for this could lie in a higher familiarity 
among TC physicians with this test, or a higher 
adherence to clinical guidelines. However, the rate 
of patients with CSM in both groups was higher 
to the one reported in previous studies (36% in 
the PICTURE Registry [11]) or in studies about 
syncope conducted in Emergency Units in Spain 
(0.4% in the GESINUR Study [13]).
Results of the ILR
The study showed significant differences in the 
final diagnosis rate among SC patients (55% with final 
diagnosis) vs. TC patients (31% diagnosis). The main 
difference lies in the presence of a higher number 
of bradycardias in the SC group. There are reasons 
which might explain this fact; thus, the more frequent 
use of EPS in TCs could have detected a group of 
patients with higher risk of bradycardia, as patients 
with first grade infra-Hisian block, or with prolonged 
sinus node recovery time, with direct indication for 
pacemaker instead of ILR. Something similar could 
be applied to CSM, more frequent in TCs. Finally, 
even though both groups presented a similar rate of 
patients with recurrent syncope, the total number 
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of syncopes and the presentation pattern in these 
patients was not ascertained, and could be different 
in both both groups. These results probably indicate 
that the selection of population is conducted differ-
ently in both types of centers; this may have a direct 
impact on the performance obtained, not so much 
due to a different cost–effectiveness of the device, 
but because a different initial population has been 
studied in each of them (SC vs. TC).
Diagnosis rates in the TC group are very 
similar to those described in previous studies 
(28% [11], 24% [12]) with similar populations. 
However, the lack of previous studies in the pa-
tient population from SC does not allow making 
any comparisons.
The type of final diagnosis was also different 
between both cohorts; the TC group presented 
a prevalence of neurally mediated events (20% vs. 
4%), while the SC group presented more events 
associated with bradycardias (74% vs. 60%). Pa-
tient selection may play a role in these findings, 
as those patients more prone to suffering severe 
bradycardias might have been previously excluded 
in TCs through the use of EPS. Another possible 
explanation could be a different interpretation of 
the bradycardia mechanisms, and consequently 
of the final diagnosis, depending on each center. 
In SCs, the arrhythmic etiology of events with 
bradycardia could be more frequently accepted, 
while those same registries could be interpreted 
as neurocardiogenic in TCs.
The treatment rate in both cohorts was very 
similar, though logically pacemakers were more 
frequently implanted in the SC group, according to 
the predominant interpretation of the bradycardiac 
episodes in these centers.
One important aspect is device safety; as 
previously described, there were no differences in 
mortality rate between both groups. This fact can 
be explained by the low number of deaths, as well 
as by the previous selection of patients conducted 
by the researchers, who would use the ILR only 
when a low risk of fatal events was accepted. The 
global rate of mortality is similar to the one in other 
previous publications, which ranges between 3.9% 
and 5% [12, 14].
Limitations of the study
The Spanish Reveal Registry is an observa-
tional registry and therefore, results should be 
interpreted as such. However, this information may 
complement data from controlled and randomized 
studies, and may be more accurate regarding what 
happens in daily clinical practice.
Given the low number of electrograms sent to 
the database, it is impossible to use them for the 
interpretation of events, and most diagnoses rely 
only on the clinical judgment of the responsible 
physicians.
Even though patients lost during follow-up 
may introduce a bias in the study results, there 
were similar rates of loss in both groups; and, 
moreover, our loss figures are consistent with 
those reported by other authors [11], and seem 
difficult to improve in this type of studies.
Conclusions
Patients considered for ILR implantation have 
a similar demographic and clinical profile in centers 
with and without EPS availability but a different 
diagnostic strategy used, with EPS and CSM con-
ducted more often in TCs, resulting in a different 
selection of the final population receiving the 
device, which probably explains the higher rates 
of final diagnosis obtained in patients from SCs. In 
both populations, bradyarrhythmias were the most 
frequent events, though the rate of events of an 
assumed  neurocardiogenic origin was significantly 
higher in TCs.
Although the strategy of using an ILR in these 
patients seems to be safe in both populations, 
even when no invasive tests are conducted before 
implantation, the low number of events precludes 
a detailed analysis of this important issue.
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